Education
Bachelor of Science: University of Alberta Alberta, Canada, 1990 (Molecular Biology)
Doctor of Medicine: University of Alberta Alberta, Canda, 1994
Certifications
American Board of Urology (Certification Date: 02-28-2006 )
Clinical Interests
Urology
Bladder Cancer
Kidney Cancer
Prostate Cancer
Testicular Cancer
Ureteral Cancer
Urogenital Cancers
Specialities
Urology
Publications
Peer Reviewed Publications
Pohar K.; Sheinfeld J. (01-01-2001. ) When is partial ureterectomy acceptable for transitional-cell carcinoma of the ureter?.Journal of Endourology, , 15 (4 ) ,405-408 More Information
Esteller M.; Cordon-Cardo C.; Corn P.G.; Meltzer S.J.; Pohar K.S.; Watkins D.N.; Capella G.; Peinado M.A.; Matias-Guiu X.; Prat J.; Baylin S.B.; Herman J.G. (04-01-2001. ) p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2 .Cancer Research, , 61 (7 ) ,2816-2821
Lu M.L.; Charytonowicz E.; Cordon-Cardo C.; Rabbani F.; Dalbagni G.; Pohar K.S.; Wikman F.; Orntoft T.F.; Zhang Z.; Yu G. (01-01-2002. ) Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by c .Clinical Cancer Research, , 8 (1 ) ,171-179
Di Como C.J.; Urist M.J.; Babayan I.; Drobnjak M.; Hedvat C.V.; Teruya-Feldstein J.; Pohar K.; Hoos A.; Cordon-Cardo C. (01-01-2002. ) p63 expression profiles in human normal and tumor tissues .Clinical Cancer Research, , 8 (2 ) ,494-501
Pohar K.; Rabbani F.; Bosl G.; Motzer R.; Bajorin D.; Sheinfeld J. (10-01-2003. ) Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinom.Journal of Urology, , 170 (4 I ) ,1155-1158 More Information
Pohar K.; Gong M.; Bahnson R.; Miller E.; Clinton S. (05-01-2003. ) Tomatoes, lycopene and prostate cancer: A clinician's guide for counseling those at risk for prostat.World Journal of Urology, , 21 (1 ) ,9-14 More Information
Pohar K.S.; Smith N.D. (01-01-2015. ) Management of the urethra in the cystectomy patient.Bladder Cancer Diagnosis and Clinical Management, , 184-189 More Information
Calhoun A.N.; Pohar K.S. (01-01-2014. ) Guideline-Based Management of Muscle-Invasive Bladder Cancer: NCCN, ICUD, and EAU.Management of Bladder Cancer A Comprehensive Text with Clinical Scenarios, , 457-463 More Information
Schafer J.M.; Song N.J.; Xiao T.; Gauntner T.D.; Jung K.J.; Fitts E.G.; Kumar K.; Jeon H.S.; Elaoud R.A.; Reynolds K.; Caruso V.M.; Levin T.G.; McConkey D.; Lee C.T.; Pohar K.S.; Clinton S.K.; Carson W.; Chung D.; Li Z.; Sundi D. (10-02-2025. ) T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunol.Journal for Immunotherapy of Cancer, , 13 (10 ) , More Information
Gore J.L.; Wolff E.M.; Nash M.G.; Comstock B.A.; Gilbert S.M.; Chang S.S.; Chisolm S.; MacLean D.B.; Wright J.L.; Kates M.R.; Pohar K.S.; Guzzo T.J.; Bivalacqua T.J.; Nepple K.G.; Montgomery J.S.; Scarpato K.R.; Woldu S.L.; Master V.A.; Chen D.Y.T.; Mossanen M.; Daneshmand S.; O'Neil B.B.; Tyson M.D.; Westerman M.E.; Kamat A.M.; Mansour A.M.; Chamie K.; Riggs S.B.; Kukreja J.B.; Modi P.K.; Garg T.; Peyton C.C.; Nix J.W.; Dickstein R.; Gadzinski A.J.; Sankin A.; Shore N.D.; Lane B.R.; Bassett J.C.; Patel S.; Morris D.S.; Macleod L.C.; Lee E.K.; Ritch C.R.; Follmer K.M.; Lee J.R.; Kim S.M.; Kessler L.G.; Smith A.B. (02-01-2026. ) Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therap.Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, , 44 (4 ) ,274-285 More Information
Motzer R.J.; Carducci M.A.; Fishman M.; Hancock S.L.; Hauke R.J.; Hudes G.R.; Kantoff P.; Kuzel T.M.; Lange P.H.; Levine E.G.; Logothetis C.; Margolin K.A.; Pili R.; Pohar K.S.; Redman B.G.; Richey S.; Robertson C.N.; Samlowski W.E.; Sheinfeld J.; Urban D.A. (01-01-2005. ) Kidney cancer: Clinical practice guidelines .Jnccn Journal of the National Comprehensive Cancer Network, , 3 (1 ) ,84-93
Motzer R.J.; Bolger G.B.; Boston B.; Carducci M.A.; Fishman M.; Hancock S.L.; Hauke R.J.; Hudes G.R.; Jonasch E.; Kantoff P.; Kuzel T.M.; Lange P.H.; Levine E.G.; Logothetis C.; Margolin K.A.; Pohar K.; Redman B.G.; Robertson C.N.; Samlowski W.E.; Sheinfeld J. (01-01-2006. ) Kidney cancer clinical practice guidelines in oncology.Jnccn Journal of the National Comprehensive Cancer Network, , 4 (10 ) ,1072-1081 More Information
Motzer R.J.; Bolger G.B.; Boston B.; Carducci M.A.; Fishman M.; Hancock S.L.; Hauke R.J.; Hudes G.R.; Jonasch E.; Kantoff P.; Kuzel T.M.; Lange P.H.; Levine E.G.; Logothetis C.; Margolin K.A.; Pohar K.S.; Redman B.G.; Robertson C.N.; Samlowski W.E.; Sheinfeld J. (01-01-2006. ) Testicular cancer clinical practice guidelines in oncology.Jnccn Journal of the National Comprehensive Cancer Network, , 4 (10 ) ,1038-1058 More Information
Shah K.; Pohar K. (09-01-2007. ) State-of-the-art surgical management of testicular tumors.Expert Review of Anticancer Therapy, , 7 (9 ) ,1301-1308 More Information
Cegala D.J.; Bahnson R.R.; Clinton S.K.; David P.; Gong M.C.; Monk J.P.; Nag S.; Pohar K.S. (01-01-2008. ) Information seeking and satisfaction with physician-patient communication among prostate cancer surv.Health Communication, , 23 (1 ) ,62-69 More Information
Dangle P.P.; Wang W.P.; Pohar K.S. (01-01-2008. ) Vesicoenteric, vesicovaginal, vesicocutaneous fistula -an unusual complication with intravesical mit .Canadian Journal of Urology, , 15 (5 ) ,4269-4272
Montie J.E.; Clark P.E.; Eisenberger M.A.; El-Galley R.; Greenberg R.E.; Herr H.W.; Hudes G.R.; Kuban D.A.; Kuzel T.M.; Lange P.H.; Lele S.M.; Michalski J.; Patterson A.; Pohar K.S.; Richie J.P.; Sexton W.J.; Shipley W.U.; Small E.J.; Trump D.L.; Walther P.J.; Wilson T.G. (01-01-2009. ) Bladder cancer.Jnccn Journal of the National Comprehensive Cancer Network, , 7 (1 ) ,8-38 More Information
Dangle P.; Wang W.; Pohar K. (11-11-2008. ) Inflammatory myofibroblastic tumor of epididymis: A case report and review of literature.World Journal of Surgical Oncology, , 6 , More Information
Dangle P.; Zaharieva B.; Jia H.; Pohar K. (11-02-2009. ) Ras-MAPK pathway as a therapeutic target in cancer - Emphasis on bladder cancer.Recent Patents on Anti Cancer Drug Discovery, , 4 (2 ) ,125-136 More Information
Chapman D.; Pohar K.; Gong M.; Bahnson R. (09-01-2009. ) Preoperative hydronephrosis as an indicator of survival after radical cystectomy.Urologic Oncology Seminars and Original Investigations, , 27 (5 ) ,491-495 More Information
Dangle P.; Gong M.; Bahnson R.; Pohar K. (02-01-2010. ) How Do Commonly Performed Lymphadenectomy Templates Influence Bladder Cancer Nodal Stage?.Journal of Urology, , 183 (2 ) ,499-504 More Information
Abaza R.; Dangle P.; Gong M.; Bahnson R.; Pohar K. (01-01-2012. ) Quality of lymphadenectomy is equivalent with robotic and open cystectomy using an extended template.Journal of Urology, , 187 (4 ) ,1200-1205 More Information
Perrino C.; Pohar K.; Zynger D. (04-01-2012. ) Urinary bladder chondroma.Virchows Archiv, , 460 (4 ) ,437-438 More Information
Korytko T.; Lowe G.; Jimenez R.; Pohar K.; Martin D. (09-01-2012. ) Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma re.Urologic Oncology Seminars and Original Investigations, , 30 (5 ) ,602-606 More Information
D'Souza A.M.; Pohar K.S.; Arif T.; Geyer S.; Zynger D.L. (10-01-2012. ) Retrospective analysis of survival in muscle-invasive bladder cancer: Impact of pT classification, n.Virchows Archiv, , 461 (4 ) ,467-474 More Information
Clark P.E.; Spiess P.E.; Agarwal N.; Biagioli M.C.; Eisenberger M.A.; Greenberg R.E.; Herr H.W.; Inman B.A.; Kuban D.A.; Kuzel T.M.; Lele S.M.; Michalski J.; Pagliaro L.; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Porter M.P.; Richie J.P.; Sexton W.J.; Shipley W.U.; Small E.J.; Trump D.L.; Wile G.; Wilson T.G.; Dwyer M.; Ho M. (05-01-2013. ) Penile cancer.Jnccn Journal of the National Comprehensive Cancer Network, , 11 (5 ) ,594-615 More Information
Clark P.E.; Agarwal N.; Biagioli M.C.; Eisenberger M.A.; Greenberg R.E.; Herr H.W.; Inman B.A.; Kuban D.A.; Kuzel T.M.; Lele S.M.; Michalski J.; Pagliaro L.C.; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Porter M.P.; Richie J.P.; Sexton W.J.; Shipley W.U.; Small E.J.; Spiess P.E.; Trump D.L.; Wile G.; Wilson T.G.; Dwyer M.; Ho M. (04-01-2013. ) Bladder cancer: Clinical practice guidelines in oncology.Jnccn Journal of the National Comprehensive Cancer Network, , 11 (4 ) ,446-475 More Information
Pohar K. (09-01-2013. ) The anatomic extent and completeness of pelvic lymphadenectomy is what matters.Current Opinion in Urology, , 23 (5 ) ,444-448 More Information
D'Souza A.M.; Phillips G.S.; Pohar K.S.; Zynger D.L. (01-01-2013. ) Clinicopathologic characteristics and overall survival in patients with bladder cancer involving the.Virchows Archiv, , 463 (6 ) ,811-818 More Information
Perrino C.M.; Fichtenbaum E.J.; Pohar K.S.; Zynger D.L. (01-01-2013. ) Challenges in the pathological reporting of urothelial carcinoma involving prostatic transurethral r.Pathology, , 45 (7 ) ,664-669 More Information
Nguyen H.T.; Pohar K.S.; Jia G.; Shah Z.K.; Mortazavi A.; Zynger D.L.; Wei L.; Clark D.; Yang X.; Knopp M.V. (01-01-2014. ) Improving bladder cancer imaging using 3-t functional dynamic contrast-enhanced magnetic resonance i.Investigative Radiology, , 49 (6 ) ,390-395 More Information
Nguyen H.T.; Jia G.; Shah Z.K.; Pohar K.; Mortazavi A.; Zynger D.L.; Wei L.; Yang X.; Clark D.; Knopp M.V. (05-01-2015. ) Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contra.Journal of Magnetic Resonance Imaging, , 41 (5 ) ,1374-1382 More Information
Grainger E.M.; Hadley C.W.; Moran N.E.; Riedl K.M.; Gong M.C.; Pohar K.; Schwartz S.J.; Clinton S.K. (08-28-2015. ) A comparison of plasma and prostate lycopene in response to typical servings of tomato soup, sauce o.British Journal of Nutrition, , 114 (4 ) ,596-607 More Information
Shen H.M.; D'Souza A.M.; Green I.F.; Pohar K.S.; Mortazavi A.; Zynger D.L. (09-01-2015. ) Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chem.Human Pathology, , 46 (9 ) ,1367-1375 More Information
Nguyen H.T.; Shah Z.K.; Mortazavi A.; Pohar K.S.; Wei L.; Jia G.; Zynger D.L.; Knopp M.V. (05-01-2017. ) Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant .European Radiology, , 27 (5 ) ,2146-2152 More Information
Kent L.N.; Rakijas J.B.; Pandit S.K.; Westendorp B.; Chen H.Z.; Huntington J.T.; Tang X.; Bae S.; Srivastava A.; Senapati S.; Koivisto C.; Martin C.K.; Cuitino M.C.; Perez M.; Clouse J.M.; Chokshi V.; Shinde N.; Kladney R.; Sun D.; Perez-Castro A.; Matondo R.B.; Nantasanti S.; Mokry M.; Huang K.; Machiraju R.; Fernandez S.; Rosol T.J.; Coppola V.; Pohar K.S.; Pipas J.M.; Schmidt C.R.; De Bruin A.; Leone G. (08-01-2016. ) E2f8 mediates tumor suppression in postnatal liver development.Journal of Clinical Investigation, , 126 (8 ) ,2955-2969 More Information
Clark P.E.; Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Efstathiou J.A.; Flaig T.W.; Friedlander T.; Greenberg R.E.; Guru K.A.; Hahn N.; Herr H.W.; Hoimes C.; Inman B.A.; Kader A.K.; Kibel A.S.; Kuzel T.M.; Lele S.M.; Meeks J.J.; Michalski J.; Montgomery J.S.; Pagliaro L.C.; Pal S.K.; Patterson A.; Petrylak D.; Plimack E.R.; Pohar K.S.; Porter M.P.; Sexton W.J.; Siefker-Radtke A.O.; Sonpavde G.; Tward J.; Wile G.; Dwyer M.A.; Smith C. (10-01-2016. ) Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines.Jnccn Journal of the National Comprehensive Cancer Network, , 14 (10 ) ,1213-1224 More Information
Dangle P.; Bahnson R.; Pohar K. (01-01-2009. ) How close are we to establishing standards of lymphadenectomy for invasive bladder cancer?.Therapeutic Advances in Urology, , 1 (3 ) ,167-174 More Information
Lavery H.; Bahnson R.; Sharp D.; Pohar K. (01-01-2009. ) Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors.Therapeutic Advances in Urology, , 1 (4 ) ,199-207 More Information
Hussein A.A.; Hinata N.; Dibaj S.; May P.R.; Kozlowski J.D.; Abol-Enein H.; Abaza R.; Eun D.; Khan M.S.; Mohler J.L.; Agarwal P.; Pohar K.; Sarle R.; Boris R.; Mane S.S.; Hutson A.; Guru K.A. (06-01-2017. ) Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion.BJU International, , 119 (6 ) ,879-884 More Information
Tretter E.; Ebel J.; Pohar K.; Zynger D. (03-01-2017. ) Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer?.Human Pathology, , 61 ,190-198 More Information
Li R.X.; Li X.L.; Li Z.; Jiao Y.; Zhao Z.G.; Wang H.; Zhang B.; Jia H.T.; Pohar K. (06-28-2016. ) Transcription factors E2F3 regulates cytokine response in invasive bladder cancer .Chinese Journal of Cancer Prevention and Treatment, , 23 (12 ) ,768-793
Kent L.N.; Bae S.; Tsai S.Y.; Tang X.; Srivastava A.; Koivisto C.; Martin C.K.; Ridolfi E.; Miller G.C.; Zorko S.M.; Plevris E.; Hadjiyannis Y.; Perez M.; Nolan E.; Kladney R.; Westendorp B.; De Bruin A.; Fernandez S.; Rosol T.J.; Pohar K.S.; Pipas J.M.; Leone G. (03-01-2017. ) Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma.Journal of Clinical Investigation, , 127 (3 ) ,830-842 More Information
Lavery H.; Zaharieva B.; McFaddin A.; Heerema N.; Pohar K. (04-07-2017. ) A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.BMC Cancer, , 17 (1 ) , More Information
Daneshmand S.; Schuckman A.K.; Bochner B.H.; Cookson M.S.; Downs T.M.; Gomella L.G.; Grossman H.B.; Kamat A.M.; Konety B.R.; Lee C.T.; Pohar K.S.; Pruthi R.S.; Resnick M.J.; Smith N.D.; Witjes J.A.; Schoenberg M.P.; Steinberg G.D. (01-01-2014. ) Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: Review of the clinic.Nature Reviews Urology, , 11 (10 ) ,589-596 More Information
Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Clark P.E.; Downs T.M.; Efstathiou J.A.; Flaig T.W.; Friedlander T.; Greenberg R.E.; Guru K.A.; Hahn N.; Herr H.W.; Hoimes C.; Inman B.A.; Jimbo M.; Kader A.K.; Lele S.M.; Meeks J.J.; Michalski J.; Montgomery J.S.; Pagliaro L.C.; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Porter M.P.; Preston M.A.; Sexton W.J.; Siefker-Radtke A.O.; Sonpavde G.; Tward J.; Wile G.; Dwyer M.A.; Gurski L.A. (10-01-2017. ) Bladder cancer, version 5.2017: Clinical practice guidelines in oncology.Jnccn Journal of the National Comprehensive Cancer Network, , 15 (10 ) ,1240-1267 More Information
Daneshmand S.; Patel S.; Lotan Y.; Pohar K.; Trabulsi E.; Woods M.; Downs T.; Huang W.; Jones J.; O'Donnell M.; Bivalacqua T.; DeCastro J.; Steinberg G.; Kamat A.; Resnick M.; Konety B.; Schoenberg M.; Jones J.S.; Bazargani S.; Djaladat H.; Schuckman A.; Cookson M.; Cross B.; Stratton K.; Lallas C.D.; Gomella L.; Mann M.; Johnson M.; Pierorazio P.; McKiernan J.; Wenske S.; Sankin A.; Merrill M.; Shabsigh A.; Nielsen M.; Pruthi R.; Smith A.; Shah J.B.; Taylor J.; Weight C. (05-01-2018. ) Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of.Journal of Urology, , 199 (5 ) ,1158-1165 More Information
Daneshmand S.; Bazargani S.T.; Bivalacqua T.J.; Holzbeierlein J.M.; Willard B.; Taylor J.M.; Liao J.C.; Pohar K.; Tierney J.; Konety B. (08-01-2018. ) Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicent.Urologic Oncology Seminars and Original Investigations, , 36 (8 ) ,361-361.e6 More Information
Nguyen H.T.; Mortazavi A.; Pohar K.S.; Zynger D.L.; Wei L.; Shah Z.K.; Jiaa G.; Knopp M.V. (01-01-2017. ) Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted.Bladder Cancer, , 3 (4 ) ,237-244 More Information
Smith A.B.; Daneshmand S.; Patel S.; Pohar K.; Trabulsi E.; Woods M.; Downs T.; Huang W.; Taylor J.; Jones J.; O'Donnell M.; Bivalacqua T.; DeCastro J.; Steinberg G.; Kamat A.; Resnick M.; Konety B.; Schoenberg M.; Jones J.S.; Lotan Y. (01-01-2019. ) Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveilla.BJU International, , 123 (1 ) ,35-41 More Information
Flaig T.W.; Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Downs T.M.; Efstathiou J.A.; Friedlander T.; Greenberg R.E.; Guru K.A.; Hahn N.; Herr H.W.; Hoimes C.; Inman B.A.; Jimbo M.; Kader A.K.; Lele S.M.; Meeks J.J.; Michalski J.; Montgomery J.S.; Pagliaro L.C.; Pal S.K.; Patterson A.; Petrylak D.P.; Plimack E.R.; Pohar K.S.; Porter M.P.; Preston M.A.; Sexton W.J.; Siefker-Radtke A.O.; Tward J.; Wile G.; Johnson-Chilla A.; Dwyer M.A.; Gurski L.A. (09-01-2018. ) NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines.Jnccn Journal of the National Comprehensive Cancer Network, , 16 (9 ) ,1041-1053 More Information
Soria F.; D'Andrea D.; Pohar K.; Shariat S.F.; Lotan Y. (11-01-2018. ) Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: Any ro.Current Opinion in Urology, , 28 (6 ) ,577-583 More Information
Williams S.B.; Kamat A.M.; Chamie K.; Froehner M.; Wirth M.P.; Wiklund P.N.; Black P.C.; Steinberg G.D.; Boorjian S.A.; Daneshmand S.; Goebell P.J.; Pohar K.S.; Shariat S.F.; Thalmann G.N. (06-01-2018. ) Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.European Urology Oncology, , 1 (2 ) ,91-100 More Information
Lotan Y.; Bivalacqua T.J.; Downs T.; Huang W.; Jones J.; Kamat A.M.; Konety B.; Malmström P.U.; McKiernan J.; O’Donnell M.; Patel S.; Pohar K.; Resnick M.; Sankin A.; Smith A.; Steinberg G.; Trabulsi E.; Woods M.; Daneshmand S. (06-01-2019. ) Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review.Nature Reviews Urology, , 16 (6 ) ,377-386 More Information
Nguyen H.T.; Shah Z.K.; Mortazavi A.; Pohar K.S.; Wei L.; Zynger D.L.; Knopp M.V. (10-01-2019. ) Periodically rotated overlapping parallel lines with enhanced reconstruction acquisition to improve .Medicine, , 98 (42 ) ,e17075 More Information
Flaig T.W.; Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Chang S.; Downs T.M.; Efstathiou J.A.; Friedlander T.; Greenberg R.E.; Guru K.A.; Guzzo T.; Herr H.W.; Hoffman-Censits J.; Hoimes C.; Inman B.A.; Jimbo M.; Karim Kader A.; Lele S.M.; Michalski J.; Montgomery J.S.; Nandagopal L.; Pagliaro L.C.; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Preston M.A.; Sexton W.J.; Siefker-Radtke A.O.; Tward J.; Wright J.L.; Gurski L.A.; Johnson-Chilla A. (01-01-2020. ) Bladder cancer, version 3.2020.Jnccn Journal of the National Comprehensive Cancer Network, , 18 (2 ) ,329-354 More Information
Pohar K.S. (05-01-2020. ) Blue Light Cystoscopy: Indications and Outcomes.Current Urology Reports, , 21 (5 ) , More Information
Ahmadi H.; Ladi-Seyedian S.S.; Konety B.; Pohar K.; Holzbeierlein J.M.; Kates M.; Willard B.; Taylor J.M.; Liao J.C.; Kaimakliotis H.Z.; Porten S.P.; Steinberg G.D.; Tyson M.D.; Lotan Y.; Daneshmand S. (07-01-2022. ) Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional.BJU International, , 130 (1 ) ,62-67 More Information
Stout T.E.; Regmi S.K.; Daneshmand S.; Porten S.P.; Pohar K.S.; Konety B.R. (01-01-2022. ) Clinical Utility of Rigid Blue Light Cystoscopy: Results from a Post Procedure User Survey in a Pros.Urology Practice, , 9 (1 ) ,94-99 More Information
Chappidi M.R.; Yang H.; Meng M.V.; Bivalacqua T.J.; Daneshmand S.; Holzbeierlein J.M.; Kaimakliotis H.Z.; Konety B.; Liao J.C.; Pohar K.; Steinberg G.D.; Taylor J.M.; Tyson M.D.; Willard B.; Lotan Y.; Porten S.P.; Kates M. (03-01-2022. ) Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detecti.Journal of Urology, , 207 (3 ) ,534-540 More Information
Daneshmand S.; Brummelhuis I.S.G.; Pohar K.S.; Steinberg G.D.; Aron M.; Cutie C.J.; Keegan K.A.; Maffeo J.C.; Reynolds D.L.; Raybold B.; Chau A.; Witjes J.A. (07-01-2022. ) The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery syste.Urologic Oncology Seminars and Original Investigations, , 40 (7 ) ,344-344.e9 More Information
Pohar K.S.; Patel S.; Lotan Y.; Trabulsi E.; Woods M.; Downs T.; Huang W.C.; Jones J.; Taylor J.; O'Donnell M.; Bivalacqua T.J.; DeCastro J.; Steinberg G.; Kamat A.M.; Resnick M.J.; Konety B.; Schoenberg M.; Jones J.S.; Daneshmand S. (08-01-2022. ) Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder ca.Urologic Oncology Seminars and Original Investigations, , 40 (8 ) ,382-382.e6 More Information
Flaig T.W.; Spiess P.E.; Abern M.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Chan K.; Chang S.; Friedlander T.; Greenberg R.E.; Guru K.A.; Herr H.W.; Hoffman-Censits J.; Kishan A.; Kundu S.; Lele S.M.; Mamtani R.; Margulis V.; Mian O.Y.; Michalski J.; Montgomery J.S.; Nandagopal L.; Pagliaro L.C.; Parikh M.; Patterson A.; Plimack E.R.; Pohar K.S.; Preston M.A.; Richards K.; Sexton W.J.; Siefker-Radtke A.O.; Tollefson M.; Tward J.; Wright J.L.; Dwyer M.A.; Cassara C.J.; Gurski L.A. (08-01-2022. ) Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines.Jnccn Journal of the National Comprehensive Cancer Network, , 20 (8 ) ,866-878 More Information
Alsyouf M.; Ladi-Seyedian S.S.; Konety B.; Pohar K.; Holzbeierlein J.M.; Kates M.; Willard B.; Taylor J.M.; Liao J.C.; Kaimakliotis H.Z.; Porten S.P.; Steinberg G.D.; Tyson M.D.; Lotan Y.; Daneshmand S. (02-01-2023. ) Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light.Urologic Oncology Seminars and Original Investigations, , 41 (2 ) ,109-109.e14 More Information
Chandra M.; Li R.; Parwani A.; Carson W.E.; Pohar K.; Sundi D. (09-01-2023. ) Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients’ access to novel th.Urologic Oncology Seminars and Original Investigations, , 41 (9 ) ,390-390.e17 More Information
Inman B.A.; Hahn N.M.; Stratton K.; Kopp R.; Sankin A.; Skinner E.; Pohar K.; Gartrell B.A.; Pham S.; Rishipathak D.; Mariathasan S.; Davarpanah N.; Carter C.; Steinberg G.D. (06-01-2023. ) A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-ris.European Urology Oncology, , 6 (3 ) ,313-320 More Information
Pohar K.S. (01-01-2021. ) Cystoscopy and Enhanced Diagnostics.Bladder Cancer A Practical Guide, , 9-20 More Information
Chang E.; Hahn N.M.; Lerner S.P.; Fallah J.; Agrawal S.; Kamat A.M.; Bhatnagar V.; Svatek R.S.; Jaigirdar A.A.; Bross P.; Shore N.; Kates M.; Sachse K.; Brewer J.R.; O'donnell M.A.; Steinberg G.D.; Viviano C.J.; Bloomquist E.; Ribal M.J.; Galsky M.D.; Oliver R.; Black P.C.; Al-Ahmadie H.; Brothers K.; Pohar K.; Dinney C.P.; Feng Z.; Downs T.M.; Porten S.P.; Smith A.B.; Bangs R.; Psutka S.P.; Agarwal N.; Amiri-Kordestani L.; Suzman D.L.; Pazdur R.; Kluetz P.G.; Weinstock C. (09-25-2023. ) Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.Bladder Cancer, , 9 (3 ) ,271-286 More Information
Gore J.L.; Follmer K.; Reynolds J.; Nash M.; Anderson C.B.; Catto J.W.F.; Chamie K.; Daneshmand S.; Dickstein R.; Garg T.; Gilbert S.M.; Guzzo T.J.; Kamat A.M.; Kates M.R.; Lane B.R.; Lotan Y.; Mansour A.M.; Master V.A.; Montgomery J.S.; Morris D.S.; Nepple K.G.; O'Neil B.B.; Patel S.; Pohar K.; Porten S.P.; Riggs S.B.; Sankin A.; Scarpato K.R.; Shore N.D.; Steinberg G.D.; Strope S.A.; Taylor J.M.; Comstock B.A.; Kessler L.G.; Wolff E.M.; Smith A.B. (04-01-2024. ) Interruptions in bladder cancer care during the COVID-19 public health emergency.Urologic Oncology Seminars and Original Investigations, , 42 (4 ) ,116-116.e21 More Information
Sundi D.; Collier K.A.; Yang Y.; Diaz D.A.; Pohar K.S.; Singer E.A.; Gupta S.; Carson W.E.; Clinton S.K.; Li Z.; Messing E.M. (02-01-2024. ) Roles of Androgen Receptor Signaling in Urothelial Carcinoma.Cancers, , 16 (4 ) , More Information
Ladi-Seyedian S.S.; Ghoreifi A.; Konety B.; Pohar K.; Holzbeierlein J.M.; Taylor J.; Kates M.; Willard B.; Taylor J.M.; Liao J.C.; Kaimakliotis H.Z.; Porten S.P.; Steinberg G.D.; Tyson M.D.; Lotan Y.; Daneshmand S. (04-01-2024. ) Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights fro.Cancers, , 16 (7 ) , More Information
Li R.; Hensley P.J.; Gupta S.; Al-Ahmadie H.; Babjuk M.; Black P.C.; Brausi M.; Bree K.K.; Fernández M.I.; Guo C.C.; Horowitz A.; Lamm D.L.; Lerner S.P.; Lotan Y.; Mariappan P.; McConkey D.; Mertens L.S.; Mir C.; Ross J.S.; O'Donnell M.; Palou J.; Pohar K.; Steinberg G.; Soloway M.; Spiess P.E.; Svatek R.S.; Tan W.S.; Taoka R.; Buckley R.; Kamat A.M. (12-01-2024. ) Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer.European Urology, , 86 (6 ) ,516-527 More Information
Lerner S.P.; Tangen C.; Svatek R.S.; Daneshmand S.; Pohar K.S.; Skinner E.; Schuckman A.; Sagalowsky A.I.; Smith N.D.; Kamat A.M.; Kassouf W.; Plets M.; Bangs R.; Koppie T.M.; Alva A.; La Rosa F.G.; Pal S.K.; Kibel A.S.; Canter D.J.; Thompson I.M. (10-03-2024. ) Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.New England Journal of Medicine, , 391 (13 ) ,1206-1216 More Information
Soltani-Tehrani A.M.; Kumar A.; Pohar K.S. (11-30-2024. ) Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.Translational Cancer Research, , 13 (11 ) ,6489-6502 More Information